Direct oral anticoagulants
clinical use in deep vein thrombosis and their role in cardiovascular prevention and claudication
DOI:
https://doi.org/10.47456/rbps.v26i1.51191Keywords:
Anticoagulants, Factor Xa Inhibitors, Venous Thromboembolism, Venous ThrombosisAbstract
Introduction: Direct Oral Anticoagulants (DOACs), represented by dabigatran, apixaban, rivaroxaban, and edoxaban, are widely used in the treatment of venous thromboembolism and the prevention of embolic events associated with atrial fibrillation. This article addresses the applicability of these medications in these conditions as well as in other clinical situations. Objective: To review the use of direct oral anticoagulants in deep vein thrombosis and discuss their growing application in cardiovascular prevention and the management of claudication, analyzing benefits and limitations in different clinical groups. Methods: Literature review of selected articles from PubMed and Clinical Guidelines. Results: DOACs have become the mainstay in the treatment of venous thromboembolism, enabling outpatient management of many of these cases from diagnosis. Their applicability extends to oncology patients with thrombosis, orthopedic surgical prophylaxis, cardiovascular prevention, and peripheral arterial disease. Despite the need for dose adjustments in special groups, such as chronic kidney disease patients, and restrictions in populations like pregnant women, lactating women, those with antiphospholipid syndrome, or dialysis patients, these medications have gained increasing clinical relevance. Conclusion: Since their approval, DOACs have gained popularity. In addition to treating deep vein thrombosis, they can be used for cardiovascular prevention and the symptomatic relief of intermittent claudication. However, the need for further studies remains to expand their safety and application in specific patient groups.
Downloads
References
Estimativa SBACV – SBACV [Internet]. Disponível em: https://sbacv.org.br/imprensa/estimativas/ [acessado em Dezembro de 2024].
Burihan MC, Campos W Jr. Consenso e atualização na profilaxia e no tratamento do tromboembolismo venoso, 1ª ed. Rio de Janeiro: Guanabara Koogan; 2019. 56 p.; ISBN 9788527736114.
Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e44S-e88S. doi: 10.1378/chest.11-2292. PMID: 22315269; PMCID: PMC3278051.
Stevens SM, Woller SC, Baumann Kreuziger L, Bounameaux H, Doerschug K, Geersing GJ, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report – executive summary. Chest. 2021 Aug;160(6).
Kakkos SK, Gohel M, Baekgaard N, Bauersachs R, Bellmunt-Montoya S, Black SA, et al. Editor’s Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. European Journal of Vascular and Endovascular Surgery. 2021 Jan;61(1):9–82.
Simon SJ, Patell R, Zwicker JI, Kazi DS, Hollenbeck BL. Venous Thromboembolism in Total Hip and Total Knee Arthroplasty. JAMA Netw Open. 2023 Dec 1;6(12):e2345883. doi: 10.1001/jamanetworkopen.2023.45883. PMID: 38039005; PMCID: PMC10692868.
Nederpelt CJ, Bijman Q, Krijnen P, Schipper IB. Equivalence of DOACS and LMWH for thromboprophylaxis after hip fracture surgery: Systematic review and meta-analysis. Injury. 2022 Mar;53(3):1169-1176. doi: 10.1016/j.injury.2021.11.052. Epub 2021 Nov 25. PMID: 34916036.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. New England Journal of Medicine. 2011 Sep 8;365(10):883–91.
Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine. 2017 Oct 5;377(14):1319–30. doi: 10.1056/NEJMoa1709118.
Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. The Lancet. 2018 Jan;391(10117):219–29. DOI: 10.1016/S0140-6736(17)32409-1.
Ramacciotti E, Agati LB, Volpiani GG, Brito KF, Ribeiro CM, Aguiar VCR et al. Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial. Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296211073922. doi: 10.1177/10760296211073922. PMID: 35043716; PMCID: PMC8796110.
Ramacciotti E, Giuliano GV, Britto KF, Agati LB, Ribeiro CM, Resende C, et al. Rivaroxaban for Patients with Intermittent Claudication. NEJM Evidence. 2024 Aug 26;3(9). doi: 10.1056/EVIDoa2400021. PMID: 39185955.
Bejjani A, Khairani CD, Assi A, Piazza G, Parham Sadeghipour, Azita Hajhossein Talasaz, et al. When Direct Oral Anticoagulants Should Not Be Standard Treatment. Journal of the American College of Cardiology. 2024 Jan 1;83(3):444–65. PMID: 38233019 DOI: 10.1016/j.jacc.2023.10.038.
Khairani CD, Bejjani A, Piazza G, Jimenez D, Monreal M, Chatterjee S, et al. Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes: Meta-Analysis of Randomized Trials. Journal of the American College of Cardiology. 2023 Jan 3;81(1):16-30. doi: 10.1016/j.jacc.2022.10.008. Epub 2022 Oct 31. PMID: 36328154; PMCID: PMC9812926.
Martin KA, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost. 2021 Aug;19(8):1874-1882. doi: 10.1111/jth.15358. Epub 2021 Jul 14. PMID: 34259389.
Zhao Y, Guo M, Li D, Xu W, Pan C, He C, et al. Pharmacokinetics and Dosing Regimens of Direct Oral Anticoagulants in Morbidly Obese Patients: An Updated Literature Review. Clinical and Applied Thrombosis/Hemostasis. 2023 Jan 1;29:10760296231153638. doi: 10.1177/10760296231153638. PMID: 36760080; PMCID: PMC9943962.
Hahn K, Lamparter M. Prescription of DOACs in Patients with Atrial Fibrillation at Different Stages of Renal Insufficiency. Adv Ther. 2023 Oct;40(10):4264-4281. doi: 10.1007/s12325-023-02544-8. Epub 2023 Aug 18. PMID: 37594666; PMCID: PMC10499752.
Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021 Oct 9;23(10):1612-1676. doi: 10.1093/europace/euab065. Erratum in: Europace. 2021 Oct 9;23(10):1676. doi: 10.1093/europace/euab157. PMID: 33895845; PMCID: PMC11636576.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Brazilian Journal of Health Research
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The Revista Brasileira de Pesquisa em Saúde (RBPS) adopts the CC BY 4.0 license, which means that authors retain the copyright of the works they submit to the journal. Authors are responsible for declaring that their contribution is an original manuscript, that it has not been previously published, and that it is not under simultaneous review by another scientific journal. Upon submitting the manuscript, authors grant RBPS the exclusive right of first publication, subject to peer review.
Authors are permitted to enter into additional contracts for the non-exclusive distribution of the version published by RBPS (for example, in institutional repositories or as a book chapter), provided that due acknowledgment of authorship and of initial publication by RBPS is given. Authors are also encouraged to make their work available online (for example, in institutional repositories or on their personal pages) after its initial publication in the journal, with due acknowledgment of authorship and of the original publication by RBPS.
Accordingly, under the CC BY 4.0 license, readers have the right to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially;
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
